ziprasidone / Generic mfg. - LARVOL DELTA

Clinical trial to study the effect of an already authorized drug on othernpathologies by administering it to people with a recent diagnosis ofnschizophrenia. (clinicaltrialsregister.eu) - P2/3 | N=37 | Recruiting | Sponsor: Fundacion Para La Gestion De La Investigacion En Salud De Sevilla | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Psychiatry • Schizophrenia

Female Sexual Dysfunction Induced by Second-Generation Antipsychotic Drugs-A Disproportionality Analysis Based on the FAERS Database. (PubMed, Schizophr Bull) - "This pharmacovigilance study highlights significant associations between specific SGAs and female sexual dysfunction. Disproportionality signals vary by drug, symptom type, and prolactin-related mechanisms. Clinicians should consider sexual side effects in treatment decisions and monitor patients accordingly. Further prospective studies are warranted."

Journal • CNS Disorders • Mental Retardation • Psychiatry • Sexual Disorders

Missing the Forest for the Trees: Delayed Diagnosis and Management of Treatment Resistant Schizophrenia. (PubMed, Psychopharmacol Bull) - "Despite multiple antipsychotic trials (quetiapine, risperidone, ziprasidone), the patient remained symptomatic, with a PANSS score of 156, consistent with treatment-resistant schizophrenia (TRS). Early use of standardized tools like PANSS in the general medical setting may be useful in differentiating psychiatric from medical causes and can expedite treatment. Though clozapine remains first-line for TRS, 45-70% may not respond to monotherapy.5,6,7 ECT augmentation was effective in our case, but evidence remains mixed,9 highlighting the need for further research into optimal TRS augmentation strategies."

Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Diabetes • Hematological Disorders • Infectious Disease • Metabolic Disorders • Myocardial Infarction • Nephrology • Psychiatry • Pulmonary Embolism • Respiratory Diseases • Schizophrenia • Type 2 Diabetes Mellitus • Vasculitis

Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders: A Systematic Review, Meta-Analysis, and Long-Term Prospective Evidence. (PubMed, J Child Adolesc Psychopharmacol) - "Several SGAs produce short-term symptom reductions versus placebo in children and adolescents with schizophrenia-spectrum disorders, with heterogeneity in TEAE risk across agents. Evidence for long-term maintenance and continuation remains limited, underscoring the need for adequately powered randomized continuation trials to guide sustained treatment in this population."

Journal • Retrospective data • Review • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

The association between psychotropic medications and cognitive functioning in bipolar disorder. (PubMed, Int J Bipolar Disord) - "Prescribers may consider limiting the administration of the medications which can affect cognitive functioning. Interventions should be further developed for people with bipolar disorder to improve their cognitive functioning and quality of life."

Journal • Bipolar Disorder • CNS Disorders • Cognitive Disorders • Mood Disorders • Psychiatry

An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (clinicaltrials.gov) - P4 | N=5 | Terminated | Sponsor: Ohio State University | N=60 ➔ 5 | Trial completion date: Jun 2026 ➔ Jan 2026 | Recruiting ➔ Terminated; Not able to recruit enough subjects

Enrollment change • Trial completion date • Trial termination • CNS Disorders • Inflammation • Psychiatry • Schizophrenia

Association between ABCDE bundle compliance and long-term outcomes: a secondary longitudinal analysis. (PubMed, Intensive Care Med) - P3 | "In this multi-site cohort with high-fidelity bundle compliance, greater bundle compliance was associated with less disability in instrumental activities of daily living and better health-related quality of life at 12 months, though associations were inconsistent and absent across other domains. Future research should evaluate integrated bundle care with post-discharge interventions to optimize long-term recovery."

Compliance • Journal • CNS Disorders • Cognitive Disorders • Critical care • Respiratory Diseases

In vitro recapitulation of drug metabolite partitioning into the bile and blood using the icHep system consisting of hepatocytes with an induced open-form bile canaliculus. (PubMed, Chem Biol Interact) - "Ziprasidone sulfoxide and mycophenolic acid glucuronide were predominantly recovered from blood-side chamber, whereas celecoxib carboxylic acid and SN-38 glucuronide were preferentially excreted into the bile-side chamber. Overall, the icHep system enables evaluation of drug metabolite partitioning into the bile and blood side. Hence, this system represents a physiologically relevant in vitro system for human pharmacokinetic studies."

Journal • Preclinical • CLDN1 • TJP1

Drug utilisation of antipsychotics and lithium in Sweden 2008-2021 - a nationwide study of children aged 5-17 years. (PubMed, Eur Child Adolesc Psychiatry) - "Risperidone is the only antipsychotic approved for younger children. Aripiprazole is approved for older children, ziprasidone and lurasidone for adolescents...In girls aged 12-17, aripiprazole and quetiapine were most common...The use of antipsychotics has increased, with the proportion of girls starting treatment at the end of study period exceeding that of boys. A considerable proportion of prescriptions was off-label, even when considering national guidelines."

Journal • CNS Disorders • Mental Retardation • Pediatrics • Psychiatry

Efficacy of Different Combination Therapies for Mania in Bipolar Disorder: A Systematic Review and Meta-Analysis. (PubMed, Brain Behav) - "Although the efficacy of ziprasidone plus mood stabilizers is comparable to that of olanzapine plus mood stabilizers in the treatment of manic episodes of bipolar disorder, ziprasidone offers advantages in improving manic symptoms (YMRS scores), reducing adverse events, and enhancing neuroendocrine indicators. It may serve as a favorable alternative in clinical practice. Further high-quality, multicenter, large-sample studies are needed to confirm its efficacy and safety."

Clinical • Journal • Retrospective data • Review • Bipolar Disorder • CNS Disorders • Endocrine Cancer • Mood Disorders • Psychiatry • BDNF

Treatment of depressive episodes with mixed features: A systematic review and meta-analysis. (PubMed, Gen Hosp Psychiatry) - "Limited but consistent RCT evidence supports lurasidone and ziprasidone for mixed-feature depression, while other interventions showed no clear benefit. Standardized diagnostic definitions and additional high-quality trials are essential to refine therapeutic recommendations and reduce heterogeneity."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Second-generation antipsychotics - Cardiac ion channel modulation and QT interval disturbances: A review. (PubMed, Biomol Biomed) - "A narrative literature review was conducted using PubMed, Web of Science, and Google Scholar, without year restrictions, focusing on English-language experimental and clinical studies related to clozapine, olanzapine, risperidone, quetiapine, and ziprasidone. Notably, the observed variability in the ratio of half-maximal inhibitory concentration to maximum free plasma concentration (IC₅₀/Cmax,free) reflects its dependence on both the degree of hERG inhibition and the pharmacokinetic properties specific to each SGA. Additionally, several SGAs affect other potassium, sodium, and calcium currents, which may either mitigate or exacerbate the consequences of IKr inhibition. In conclusion, QT interval prolongation associated with SGAs is primarily driven by hERG potassium channel blockade, although the degree of this effect varies significantly among different agents. This variability highlights the necessity for electrocardiogram (ECG) monitoring and..."

Journal • Review • Cardiovascular • CNS Disorders • Psychiatry

Post-lanosterol inhibition profile based classification of commonly used prescription medications. (PubMed, Transl Psychiatry) - "Using LC-MS/MS we measured 13 post-lanosterol intermediates in control, DHCR7 +/- and DHCR7-/- human dermal fibroblasts exposed to cariprazine, nebivolol, rotigotine, buspirone, lurasidone, fluoxetine, hydroxyzine, amiodarone, spiroxamine, vilazodone and ziprasidone. In addition, DHCR7 +/- fibroblasts responded with greater sterol profile disruptions to all medications, while DHCR7 fibroblasts from patients with Smith-Lemli-Opitz syndrome showed generally a more plateaued response. Knowing the inhibition profile-based classification of medications that have a sterol inhibiting side effect might ultimately translate into safety recommendations during pregnancy and could be critical for new drug development."

Journal • DHCR7

QT interval prolongation in acute antipsychotic poisoning: systematic review and recommendations. (PubMed, Clin Toxicol (Phila)) - "Individual medication recommendations were made for amisulpride (15 articles), thioridazine (11 articles), ziprasidone (eight articles) and quetiapine (13 articles), whilst consensus statements based on limited data were made for acute ingestions of clozapine, haloperidol, iloperidone, pimozide, pipamperone, olanzapine and risperidone (14 articles in total). The QT Interval Prolongation in Clinical Toxicology Workgroup suggests the same approach for patients with overdoses of haloperidol, iloperidone, pipamperone and pimozide. The risk of torsade de pointes is likely overstated for acute antipsychotic medication overdose as a general class group, and concern should rather focus on a few specific medications."

Journal • CNS Disorders

ECG Changes Associated With Antipsychotic Use: A Case Vignette From the Emergency Department. (PubMed, Adv Emerg Nurs J) - "First- and second-generation antipsychotics, including the commonly used haloperidol and ziprasidone, are known to cause QTc prolongation, the most clinically significant ECG abnormality. Effective management requires individualized assessment, vigilant ECG and electrolyte monitoring, and informed antipsychotic selection. This case study highlights the clinical presentation and potential ECG changes associated with antipsychotic medication use in the ED."

Journal • Cardiovascular • CNS Disorders • Mental Retardation • Psychiatry • Ventricular Tachycardia

Second-Generation Antipsychotics and VTE Risk (ASH 2023) - "Events were then narrowed further to include only those associated with a single second-generation antipsychotic – aripiprazole, clozapine, olanzapine, quetiapine, and ziprasidone. There were a total of 1155 VTE events amongst the six antipsychotics, out of 180824 total reported cases. Olanzapine (308) and quetiapine (273) had the most events overall as well as the most PEs (olanzapine 224, quetiapine 204), while risperidone had the most deep vein thromboses (DVT) (103). When analyzed using the PRR (for which ziprasidone was excluded due to low number of cases and events), olanzapine and quetiapine were disproportionally associated with an increased rate of VTE (2.57 and 2.22 respectively) and PE (2.71 and 2.42 respectively)."

Cardiovascular • CNS Disorders • Hematological Disorders • Respiratory Diseases • Venous Thromboembolism

Curcumin as an Antioxidant Against Ziprasidone Induced Lipid Peroxidation in Human Plasma: Potential Relevance to Cortico Subcortical Circuit Function. (PubMed, Int J Mol Sci) - "Ziprasidone (40 ng/mL, 139 ng/mL, 250 ng/mL) significantly increased TBARS levels, but in the presence of the studied curcumin concentrations, its pro-oxidative effects were reduced by about 56%. Our results confirm that Ziprasidone in vitro may induce lipid peroxidation in human plasma, whereas curcumin protects against lipid peroxidation in human plasma caused by the antipsychotic Ziprasidone."

Journal • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Comparison of ziprasidone and olanzapine on cognitive function in patients with schizophrenia at different stages: a prospective study in Huai'an, China. (PubMed, Front Behav Neurosci) - "Patients with schizophrenia have cognitive dysfunction in the early stage of onset. The combination of ziprasidone and olanzapine can effectively improve cognitive dysfunction and promote the recovery of social functions of patients."

Journal • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Gaps in the detection of drug-drug interactions between antipsychotic and cardiometabolic medications: a multisource analysis. (PubMed, BMC Med) - "This systematic review and disproportionality analysis identified potential DDIs between antipsychotic medications and cardiometabolic medications, many of which were not captured by commonly used DDI checkers. These findings underscore the need for clinicians to consult multiple sources and apply clinical judgment when prescribing these medications. Improved integration of pharmacovigilance data into DDI checkers may enhance the identification and prevention of harmful interactions."

Journal • Cardiovascular • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Musculoskeletal Diseases • Rheumatology

Impact of selected second and third generation antipsychotics on cognitive dysfunction in schizophrenia-spectrum disorders. Systematic review and network meta-analysis. (PubMed, Int Clin Psychopharmacol) - "This study aimed to: (a) systematically review randomized controlled trials (RCTs) evaluating the cognitive effects of third-generation antipsychotics (TGAs: brexpiprazole, cariprazine, lumateperone, and lurasidone) and xanomeline-trospium; and (b) perform a network meta-analysis (NMA) including additional second-generation antipsychotics with potential procognitive effects. A systematic literature search identified eligible RCTs, which were combined with trials on aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone from a previous meta-analysis...In conclusion, selected second and TGAs, including M1/M4 receptor agonists such as xanomeline, may offer promising treatment options for cognitive dysfunction. Further research should personalize pharmacological strategies based on cognitive profiles."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Grading the Evidence- Bipolar Disorder and Schizophrenia (AACAP 2025) - "FDA approval will also be part of the metric in helping to determine recommendations. Multiple studies are available that are funded by the NIH and FDA for psychosis (primarily schizophrenia) that show high levels of evidence, ie, grades 1A and 1B for benefit with tolerable side effects including newer medications such as lurasidone. Other medications have good efficacy but higher side-effect burdens such as clozapine. Finally, some medications have inadequate separation from placebo and are not approved, such as ziprasidone and asenapine... The field of psychopharmacology for bipolar and psychotic disorders has a number of completed controlled trials that contribute to the evidence base. Clinicians can use the GRADE system to recommend medications based on the balance of efficacy vs adverse event burden to obtain symptom control.BRD, PSY, PTA"

Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Pediatrics • Psychiatry • Schizophrenia

Efficacy and Tolerability of Seven Antipsychotic Drugs in Acutely Ill Patients With Schizophrenia: A Randomized, Multicenter, Assessor-Blinded Trial. (PubMed, Am J Psychiatry) - "Eligible inpatients 18-45 years of age with schizophrenia experiencing acute exacerbation were recruited and randomized to 6 weeks of monotherapy with one of seven antipsychotic drugs: olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, perphenazine, and haloperidol. This trial fills important knowledge gaps in acute antipsychotic treatment of schizophrenia. It confirms hierarchies in efficacy and side effects of antipsychotics from related evidence."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Bipolar disorder in children, adolescents and young adults. Part 2. Therapeutic management. Recommendations under the patronage of the Executive Board of the Polish Psychiatric Association, National Consultants in the field of Psychiatry and National Consultants in Child and Adolescent Psychiatry. (PubMed, Psychiatr Pol) - "Lithium, aripiprazole, quetiapine, risperidone, olanzapine, asenapine, ziprasidone are recommended for the treatment of mania and mixed states. For the treatment of depressive episodes in bipolar disorder in children and adolescents, experts recommend lurasidone as monotherapy or olanzapine + fluoxetine as combination therapy. Although long-term treatment is a key aspect of bipolar disorder management in children and adolescents, consistent efficacy data are still lacking. Safety data indicate that the most commonly reported adverse reactions in children and adolescents treated with mood stabilizers are gastrointestinal and neurological adverse reactions, while the use of antipsychotics is mainly associated with weight gain and sedation."

Clinical guideline • Journal • Review • Anesthesia • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Glucose dysregulation signals in weight-neutral atypical antipsychotics: A pharmacovigilance-pharmacodynamic evaluation of FAERS data. (PubMed, J Affect Disord) - "Weight-neutral drugs such as ziprasidone, asenapine, lurasidone, and aripiprazole may be associated with glucose dysregulation, underscoring the need for vigilance when switching antipsychotics. This phenomenon might be attributable to their antagonistic effects on 5-HT2C receptors. However, given the exploratory nature of this study, these findings warrant further validation."

Adverse events • Journal • PK/PD data • CNS Disorders

Transferrin-Conjugated Chitosan Nanoparticles for Direct Nose-to-Brain Delivery of Ziprasidone: Pharmacokinetic and Pharmacodynamic Evaluation. (PubMed, Mol Pharm) - "Tf-NP also elicited a faster onset and sustained pharmacodynamic response. These data demonstrate that intranasal Tf-functionalized ZS nanoparticles significantly improve CNS targeting and bioavailability while mitigating systemic exposure, supporting their development as targeted therapeutics for neuropsychiatric disorders."

Journal • PK/PD data • CNS Disorders • Mental Retardation • Psychiatry